Voriconazole therapeutic drug monitoring
Open accessAbstract
We report on 28 patients who underwent voriconazole monitoring because of disease progression or toxicity. A relationship ( P < 0.025) between disease progression and drug concentration was detected. Favorable responses were observed in 10/10 patients with concentrations above 2.05 μg/ml, while disease progressed in 44% ( n = 18) of patients with concentrations below 2.05 μg/ml.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Treatment success in retrospective analyses has been associated with voriconazole serum trough concentrations of 1 to 2 mg/mL.
“Treatment success in these retrospective analyses has been associated with serum trough concentrations of 1 to 2 mg/mL.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [152]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 30 · Cited by 399
- Authors
- Smith, J., Safdar, N., Knasinski, V., Simmons, W., Bhavnani, S. M., Ambrose, P. G., & Andes, D.
- Affiliations
- University of Wisconsin–Madison (US)
- Institute for Clinical Pharmacodynamics (United States) (US)
- Corresponding author
- Andes, D.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-04
- Volume
- 50
- Issue
- 4
- Pages
- 1570-1572
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC1426935
- OpenAlex
- W2171105924
- Cited by
- 399
- References
- 30
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 8 · 2022: 3 · 2021: 9 · 2020: 13 · 2019: 12 · 2018: 15 · 2017: 9 · 2016: 19 · 2015: 24 · 2014: 22 · 2013: 26 · 2012: 31
- FWCI
- 25.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Pharmacology › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- voriconazole, therapeutic drug monitoring, antifungal agents, drug concentration, disease progression, adverse drug reactions, antifungal toxicity, treatment response
- MeSH terms
- Adult, Aged, Antifungal Agents, Female, Humans, Male, Middle Aged, Pyrimidines, Retrospective Studies, Triazoles, Drug Monitoring, Disease Progression, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
